If you’re working in pharma or biotech, you likely rely on artificial intelligence (AI) to help you identify new drug targets or plausible biomarkers for disease within large data sets. Yet AI alone isn’t enough. A large proportion of Biomedical data have errors and are unstructured. For AI models to provide reliable insights, the underlying data must be of ‘hig...

Scale your NGS analysis to match your sequencing throughput using our QIAGEN CLC Genomics cloud solution. In this webinar, you’ll learn about the flexible and powerful setup for running your NGS sequence analyses on Amazon Web Services (AWS). You’ll learn how to use QIAGEN CLC Genomics Workbench to customize workflows and send analyses to AWS Batch for execution. ...

Biomedical relationships knowledge is now required for innovative data- and analytics-driven drug discovery. It powers biomedical knowledge graph analysis, artificial intelligence (AI)-driven target identification and many more applications. In this one-hour training, you’ll get an introduction to QIAGEN Biomedical Knowledge Base. You’ll learn how to tackle appli...

Clinical exome sequencing (CES) is increasingly being adopted by small and mid-sized laboratories to diagnose genetic diseases, aid treatment decisions, and provide prognostic information. However, the exponential increase in genetic data generated from exome and genome panels poses significant workflow challenges. The ability to prioritize potentially pathogenic vari...

In its latest release, QCI Interpret for Hereditary extends its market-leading content with further advancements in Artificial Intelligence (AI) for enhanced capabilities in clinical exome NGS testing. Now, with the addition of AI-derived literature references for rare disease genes, QCI Interpret provides complete exome coverage, on top of the existing unrivalled man...

Interested in learning about new features and functionalities that have been added to IPA lately? During this webinar, we will highlight the updates from the QIAGEN IPA Fall Release and from previous releases from this year. Topics, amongst others, will be • Newly added findings and pathways • Reactome pathways • Artificial intelligence approves to pathways ...